Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma: a Phase II Trial (ANZUP 1601)

Next Previous
Trial Profile

Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma: a Phase II Trial (ANZUP 1601)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Denosumab (Primary) ; Pembrolizumab (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms KEYPAD

    • Most Recent Events

    • 24 Oct 2023 Results assessing activity and safety of the RANKL-inhibitor denosumab (D) with pembrolizumab (P) in people with pretreated advanced ccRCC presented at the 48th European Society for Medical Oncology Congress
    • 16 Oct 2023 According to an Amgen media release, data from this study will be presented at the European Society for Medical Oncology (ESMO) Congress 2023, taking place from October 20-24 in Madrid.
    • 27 Mar 2023 Planned End Date changed from 31 Mar 2023 to 4 Jun 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top